ArticleTissue engineering. Part A2021
Sustained Delivery of SB-431542, a Type I Transforming Growth Factor Beta-1 Receptor Inhibitor, to Prevent Arthrofibrosis.
Article in Tissue engineering. Part A, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- More Improved Postoperative Range-of-Motion Retention After Arthroscopic Lysis of Adhesions After Total Knee Arthroplasty Is Associated With Arthroscopic Fellowship-Trained Compared With Nonfellowship-Trained Surgeons.Arthroscopy, sports medicine, and rehabilitation · 2026Article
- Efficient multi-lineage cardiovascular differentiation of human pluripotent stem cells in animal serum-free conditions.Scientific reports · 2026Article
- Identification of TGF-β1 as a key regulator in DOX-induced cardiotoxicity.Journal of cardiothoracic surgery · 2026Article
- Novel therapeutic strategies for osteoarthritis: from mechanistic insights to precision medicine.Bone research · 2026Review
- A Narrative Review of Salivary Gland Extracellular Matrix and Sjögren's Syndrome: Research Status and Future Prospects.Biomolecules · 2026Review
- Repeated-Dose Toxicity of Lauric Acid and Its Preventive Effect Against Tracheal Hyper-Responsiveness in Wistar Rats with PossiblePharmaceuticals (Basel, Switzerland) · 2025Article
- Conditioned Medium from Human Amniotic Membrane-Derived Mesenchymal Stem Cells Modulates Inflammatory and Myofibrotic Factors in Vivo.The journal of Tehran Heart Center · 2024Article
- TGF-β signaling in health, disease, and therapeutics.Signal transduction and targeted therapy · 2024Review
- Red blood cell exposure increases chondrocyte susceptibility to oxidative stress following hemarthrosis.Osteoarthritis and cartilage · 2023Article
- Collagen Fibril Orientation Instructs Fibroblast Differentiation Via Cell Contractility.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy.Molecular cancer · 2023Review
- ALK5 Inhibition of Subconjunctival Scarring From Glaucoma Surgery: Effects of SB-431542 Compared to Mitomycin C in Human Tenon's Capsule Fibroblasts.Translational vision science & technology · 2023Article
- Toward defining the role of the synovium in mitigating normal articular cartilage wear and tear.Journal of biomechanics · 2023Article
- TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy.Frontiers in immunology · 2022Review
- [Inhibition of TGF-β promotes functional recovery of spinal cord injury in mice by reducing fibronectin deposition].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Fibrosis of the knee is a common disorder resulting from an aberrant wound healing response and is characterized by extracellular matrix deposition, joint contraction, and scar tissue formation. The principal regulator of the fibrotic cascade is transforming growth factor beta-1 (TGF-β1), a factor that induces rapid proliferation and differentiation of resident fibroblasts. In this study, we demonstrate successful inhibition of TGF-β1-driven myofibroblastic differentiation in human fibroblast-like synoviocytes using a small molecule TGF-β1 receptor inhibitor, SB-431542. We also demonstrate successful encapsulation of SB-431542 in poly(D,L-lactide-co-glycolide) (PLGA) as a potential prophylactic treatment for arthrofibrosis and characterize drug release and bioactivity in a three-dimensional collagen gel contraction assay. We assessed the effects of TGF-β1 and SB-431542 on cell proliferation and viability in monolayer cultures. Opposing dose-dependent trends were observed in cell proliferation, which increased in TGF-β1-treated cultures and decreased in SB-431542-treated cultures relative to control (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.